How to buy Regulus Therapeutics (RGLS) stock

Regulus Therapeutics Inc is a biotechnology business based in the US. Regulus Therapeutics shares (RGLS) are listed on the NASDAQ and all prices are listed in US Dollars. Regulus Therapeutics employs 23 staff and has a trailing 12-month revenue of around 0.00.

Regulus Therapeutics stock price (NASDAQ: RGLS)

Use our graph to track the performance of RGLS stocks over time.

Regulus Therapeutics shares at a glance

• Key figures

Information last updated 2021-07-22.

Latest market close	$0.99
52-week range	$0.42 - $1.97
50-day moving average	$0.90
200-day moving average	$1.24
Wall St. target price	$1.17
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-2.43

Buy Regulus Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Regulus Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Regulus Therapeutics Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Regulus Therapeutics price performance over time

Historical closes compared with the close of $0.99 from 2021-05-28

1 week (2021-07-12)	N/A
1 month (2021-06-23)	1.02%
3 months (2021-04-19)	N/A
6 months (2021-01-19)	N/A

1 year (2020-07-19)	N/A
2 years (2019-07-19)	N/A
3 years (2018-07-19)	N/A
5 years (2016-07-19)	N/A

Regulus Therapeutics financials

Revenue TTM	$10 million
Gross profit TTM	$-5,341,000
Return on assets TTM	-24.08%
Return on equity TTM	-75.24%
Profit margin	-158.06%
Book value	$0.36
Market capitalisation	$55.7 million

TTM: trailing 12 months

Shorting Regulus Therapeutics shares

There are currently 6.2 million Regulus Therapeutics shares held short by investors – that's known as Regulus Therapeutics's "short interest". This figure is 4.8% up from 5.9 million last month.

There are a few different ways that this level of interest in shorting Regulus Therapeutics shares can be evaluated.

Regulus Therapeutics's "short interest ratio" (SIR)

Regulus Therapeutics's "short interest ratio" (SIR) is the quantity of Regulus Therapeutics shares currently shorted divided by the average quantity of Regulus Therapeutics shares traded daily (recently around 7.3 million). Regulus Therapeutics's SIR currently stands at 0.85. In other words for every 100,000 Regulus Therapeutics shares traded daily on the market, roughly 850 shares are currently held short.

However Regulus Therapeutics's short interest can also be evaluated against the total number of Regulus Therapeutics shares, or, against the total number of tradable Regulus Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Regulus Therapeutics's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Regulus Therapeutics shares in existence, roughly 80 shares are currently held short) or 0.0958% of the tradable shares (for every 100,000 tradable Regulus Therapeutics shares, roughly 96 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Regulus Therapeutics.

Find out more about how you can short Regulus Therapeutics stock.

Regulus Therapeutics share dividends

We're not expecting Regulus Therapeutics to pay a dividend over the next 12 months.

Have Regulus Therapeutics's shares ever split?

Regulus Therapeutics's shares were split on a 1:12 basis on 3 October 2018. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Regulus Therapeutics shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Regulus Therapeutics shares which in turn could have impacted Regulus Therapeutics's share price.

Regulus Therapeutics share price volatility

Over the last 12 months, Regulus Therapeutics's shares have ranged in value from as little as $0.4222 up to $1.97. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Regulus Therapeutics's is 2.2622. This would suggest that Regulus Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Regulus Therapeutics overview

Regulus Therapeutics Inc. , a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS4326, an anti-miR targeting miR-17, which is in Phase 1 development for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products, which include RGLS5579 glioblastoma multiforme program; and Hepatitis B virus, non-alcoholic steatohepatitis, and cell therapies programs. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California. .

Frequently asked questions

What percentage of Regulus Therapeutics is owned by insiders or institutions?
Currently 4.95% of Regulus Therapeutics shares are held by insiders and 49.831% by institutions. How many people work for Regulus Therapeutics?
Latest data suggests 23 work at Regulus Therapeutics. When does the fiscal year end for Regulus Therapeutics?
Regulus Therapeutics's fiscal year ends in December. Where is Regulus Therapeutics based?
Regulus Therapeutics's address is: 4224 Campus Point Court, San Diego, CA, United States, 92121 What is Regulus Therapeutics's ISIN number?
Regulus Therapeutics's international securities identification number is: US75915K2006 What is Regulus Therapeutics's CUSIP number?
Regulus Therapeutics's Committee on Uniform Securities Identification Procedures number is: 75915K101